| Literature DB >> 22160321 |
Arne Wrede1, Nils G Margraf, Hans H Goebel, Günther Deuschl, Walter J Schulz-Schaeffer.
Abstract
Camptocormia is a highly disabling syndrome that occurs in various diseases but is particularly associated with Parkinson's disease (PD). Although first described nearly 200 years ago, the morphological changes associated with camptocormia are still under debate and the pathophysiology is unknown. We analyzed paraspinal muscle biopsies of 14 PD patients with camptocormia and compared the findings to sex-matched postmortem controls of comparable age to exclude biopsy site-specific changes. Camptocormia in PD showed a consistent lesion pattern composed of myopathic changes with type-1 fiber hypertrophy, loss of type-2 fibers, loss of oxidative enzyme activity, and acid phosphatase reactivity of lesions. Ultrastructurally, myofibrillar disorganization and Z-band streaming up to electron-dense patches/plaques were seen in the lesions. No aberrant protein aggregation, signs of myositis or mitochondriopathy were found, but the mitochondrial content of paraspinal muscles in patients and controls was markedly higher than known from limb biopsies. Additionally, we were able to demonstrate a link between the severity of the clinical syndrome and the degree of the myopathic changes. Because of the consistent lesion pattern, we propose criteria for the diagnosis of camptocormia in PD from muscle biopsies. The morphological changes show obvious parallels to the muscle pathology of experimental tenotomy reported in the 1970s, which depend on an intact innervation and do not occur after interruption of the myotactic reflexes. A dysregulation of the proprioception could be part of the pathogenesis of camptocormia in Parkinson's disease, particularly in view of the clinical symptoms of rigidity and loss of muscle strength.Entities:
Mesh:
Year: 2011 PMID: 22160321 PMCID: PMC3282910 DOI: 10.1007/s00401-011-0927-7
Source DB: PubMed Journal: Acta Neuropathol ISSN: 0001-6322 Impact factor: 17.088
Details of patients and biopsy findings of Parkinson disease patients
| No. | Age | Sex | Hallmarks of clinical diagnosis | Flexion angle (°) | Biopsy site | Biopsy findings | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Major findings | Minor findings | ||||||||||||||||
| No. in (14). | Duration of PD in years | Duration of camptocormia in months | Therapy: | Structural defects | Acid phosphatase activity in muscle fibers | Myofibrillar structural defects | Caliber variation | Whorled fibers | Endomysial fibrosis | Nuclear bags | Increase in internalized nuclei | Fiber type I:II | |||||
| B1 | 1 | 55 | F | 4 | 8 | 800/– | 30 | Lumbar | + | + | + | + | + | + | + | + | 10:1 |
| B2 | 2 | 59 | F | 10 | 28 | 700/– | 90 | Th12 | + | + | n.e. | + | 0 | + | + | + | 10:1 |
| B3 | 13 | 72 | M | 17 | 30 | 600/– | 80 | Lumbar | + | + | + | + | + | + | + | + | 3:1 |
| B4 | 5 | 64 | M | 7 | 32 | 1,400/– | 60 | Thoraco-lumbar | + | + | Ø | + | 0 | + | + | + | 1:1.5 |
| B5 | 8 | 68 | F | 22 | 5 | –/DBS | 70 | Th12–L1 | + | + | + | + | 0 | + | + | + | 10:1 |
| B6 | 11 | 69 | M | 15 | 12 | 300/– | 60 | L3 | + | + | + | + | + | + | + | + | 20:1 |
| B8 | 4 | 62 | M | 10 | 5 | 800/– | 30 | L1 | + | + | + | + | + | + | + | + | 20:1 |
| B9 | 10 | 68 | F | 41 | 54 | 500/DBS | 90 | Not specified | + | + | + | + | + | + | + | + | 40:1 |
| B10 | 6 | 66 | F | 11 | 36 | 800/– | 45 | Th12–L1 | n.e. | n.e. | + | + | + | + | + | 0 | n.e. |
| B11 | 9 | 68 | M | 9 | 72 | 1,350/– | 70 | Cervical | + | + | + | + | + | + | + | 0 | 1:1 |
| B12 | 7 | 67 | M | 10 | 17 | 850/– | 45 | Th10–12 | + | + | + | + | 0 | + | + | + | 1:1 |
| B13 | 3 | 61 | F | 13 | 17 | 1,200/– | 90 | Th12–L1 | + | + | Ø | + | + | + | + | + | 5:1 |
| B14 | – | 70 | M | 6 | 9 | 750/– | 30–40 | Not specified | + | + | + | + | + | + | + | + | 40:1 |
+ Biopsy findings detectable, 0 not detectable, n.e. not exploitable, Ø no material available for electron microscopy, DBS deep brain stimulation
Patients and tissue details of control patients
| Case | Age | Sex | Hallmark of clinical diagnosis | Brain autopsy findings | PM interval (h) | Muscles | Muscle findings |
|---|---|---|---|---|---|---|---|
| C1 | 79 | M | Endocarditis, pancreas carcinoma. | Without pathological changes | ~30 | Cervical paraspinal | Neurogenic atrophy, type II hypotrophy + |
| Deltoid | Neurogenic atrophy, type II hypotrophy +++ | ||||||
| C2 | 77 | F | Lung embolism | Microinfarct of cornu ammonis | 34 | Cervical paraspinal | Type II atrophy/hypotrophy + |
| Deltoid | Type II atrophy/hypotrophy ++ | ||||||
| C3 | 55 | F | Rectal carcinoma | Without pathological changes | ~48 | Cervical paraspinal | Type II atrophy ++ |
| Deltoid | Type II atrophy ++ | ||||||
| C4 | 67 | F | Hypertension | Hemorrhage of basal ganglia, old infarct | ~24 | Lumbar paraspinal | COX-def. fibers ++; type II atrophy + |
| Deltoid | Type II atrophy ++ | ||||||
| C5 | 82 | F | Endocarditis, apoplexy (left cerebral artery) | Small cerebral infarcts | ~24 | Cervical paraspinal | Lymphocytic infiltrates +++, type II atrophy+ |
| Lumbar paraspinal | Lymphocytic infiltrates +; type II atrophy++ | ||||||
| Deltoid | Lymphocytic infiltrates +++; type II atrophy++ | ||||||
| C6 | 54 | F | Acute myeloic leucemia; allogenic stem cell therapy; graft versus host reaction | Without pathological changes | 66 | Cervical paraspinal | Neurogenic ++; type II atrophy+++ |
| Lumbar paraspinal | type II atrophy+++ | ||||||
| Deltoid | Neurogenic atrophy +++; type II atrophy | ||||||
| C7 | 73 | M | Prostate carcinoma. Urosepsis, transitory ischemic attack with acute respiratory distress syndrome | Two small microinfarcts in the midbrain | ~24 | Cervical paraspinal | Type II hypotrophy +++ |
| Lumbar paraspinal | Neurogenic atrophy +++; type II hypotrophy ++ | ||||||
| Deltoid | Neurogenic atrophy ++; type II hypotrophy ++ | ||||||
| C8 | 47 | M | Sepsis, spinal canal stenosis, type II-diabetes | Without pathological changes | 24 | Cervical paraspinal | Unspecific changes |
| Lumbar paraspinal | Unspecific changes | ||||||
| Deltoid | Unspecific changes | ||||||
| C9 | 77 | M | Large cell anaplastic B-cell lymphoma, dilative cardiomyopathy | Remnants of hypoxia | 24 | Cervical paraspinal | type II atrophy+++; neurogenic atrophy + |
| Deltoid | type II atrophy++; neurogenic atrophy + | ||||||
| C10 | 54 | M | Pneumonia, sepsis, multi-organ failure | Septic embolism, severe hypoxia | 18 | Cervical paraspinal | Neurogenic atrophy +; type II fiber hypotrophy |
| Lumbar paraspinal | Neurogenic atrophy +; type II fiber hypotrophy | ||||||
| Deltoid | Type II fiber hypotrophy |
Changes within muscle biopsies were rated semiquantitatively as + mild, ++ moderate or +++ severe
Fig. 1Morphological differences between paraspinal and limb muscles in controls. Paraspinal muscles display a higher number of ragged red and COX-deficient fibers than deltoid muscles of the same control patients (a). No further morphological differences were detectable between paraspinal muscles of cervical or lumbar levels (b)
Fig. 2Myopathic changes in paraspinal muscles of camptocormia compared to controls: Increased fiber size spectrum (a H&E) and hypertrophy (g), endomysial fibrosis (c elastica van Gieson stain) and lack of type-2 fibers (e SERCA1 immunohistochemistry) in camptocormia compared to controls (b, d, f). Quantification of morphological changes are shown in h. Bar 100 μm
Fig. 3Camptocormia is characterized by myofibrillar disorganization. Loss of oxidative enzyme reaction (a NADH reaction) accompanied by pathological acid phosphatase reactivity (c) are detectable but not in controls (b, d). Ultrastructurally, myofibrillar disorganization, Z-band streaming and electron-dense patches correspond to the light microscopic lesions (e semithin section, Richardson staining, f electron microscopy). Bars a–d 100 μm, e 25 μm, f 1 μm
Fig. 4Camptocormia shows no evidence for mitochondriopathy or inflammation. Modified Gomori’s trichrome stain sometimes shows a higher content of ragged red and COX-deficient fibers in PD camptocormia biopsy tissues (a, e) than in control limb muscles (see Fig. 1) but the same holds true for the paraspinal control muscles (b, e). No evidence for inflammation was observed (c, d MHC-1 immunohistochemistry). Bars 100 μm
Fig. 5Correlating the severity of myopathic changes with clinical parameters of camptocormia, no significant correlation of the endomysial fibrosis could be found with regard to the inclination angle (a). But there was a statistically relevant correlation between the degree of endomysial fibrosis and the clinical camptocormia score, as well as a correlation between our myopathy index which was based on the relevant myopathological changes and the clinical camptocormia score (b, c thresholds: r > 0.559; p < 0.05)
Histopathological diagnosis of camptocormia in Parkinson’s disease
| Main features of the histopathological diagnosis of camptocormia are structural defects that |
| Are pale in oxidative enzyme reactions (i.e. SDH, NADH, COX) |
| Are acid phosphatase reactive |
| Show a myofibrillar disintegration, Z-band streaming or rod-like structures in the lesions by electron microscopy |
| Minor features of the diagnosis of camptocormia are |
| An increase of caliber variation, type 1-fiber hypertrophy and type 1-fiber predominance |
| Endomysial fibrosis |
| Whorled fibers |
| Increased number of internalized nuclei |
| Atrophy and loss of type 2-fibers |
| Nuclear bags |